AMAG Pharmaceuticals, Inc. to Host Conference Call on March 7, 2012 at 4:30 p.m. ET to Discuss Feraheme Clinical Trial Results

LEXINGTON, Mass.–(BUSINESS WIRE)–Mar. 6, 2012–
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced it will report
preliminary results from the first of two phase III clinical trials of Feraheme
for the treatment of iron deficiency anemia regardless of the underlying
cause after the U.S. financial markets close on Thursday, March 7, 2012.
The announcement will be followed by a conference call and webcast at
4:30 p.m. ET during which management will discuss the company’s results
of this study.

To access the conference call via telephone, please dial (877) 412-6083
from the United States or (702) 495-1202 for international access. A
telephone replay will be available from approximately 8:30 p.m. ET on
March 7, 2012 through midnight March 12, 2012. To access a replay of the
conference call, dial (855) 859-2056. The pass code for the live call
and the replay is 59989211.

The call will be webcast and accessible through the Investors section of
the Company’s website at www.amagpharma.com.
The webcast replay will be available from approximately 8:30 p.m. ET on
March 7, 2012 through midnight April 7, 2012.

About AMAG Pharmaceuticals, Inc.

AMAG Pharmaceuticals, Inc. is a biopharmaceutical company focused on the
development and commercialization of a therapeutic iron compound to
treat iron deficiency anemia. AMAG manufactures and sells Feraheme®
(ferumoxytol) Injection for intravenous use. For additional company or
product information, please visit www.amagpharma.com
or http://feraheme.com.

Feraheme is a registered trademark of AMAG Pharmaceuticals, Inc.

Source: AMAG Pharmaceuticals, Inc.

AMAG Pharmaceuticals, Inc.
Amy Sullivan, 617-498-3303